Is routine amniocentesis for advanced maternal age still indicated?

Fetal Diagnosis and Therapy

Volumn 16, Issue 6, 2001, Pages 372-377

  Dommergues, Marc ^a   Audibert, François ^a   Benattar, Clarisse ^a   Champagne, Catherine ^a   Gomel, Victor ^b   Frydman, René ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amniocentesis; Down's syndrome; Fetal nuchal translucency; Maternal age; Maternal serum screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN;

ADULT; AMNIOCENTESIS; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FETUS; FETUS ECHOGRAPHY; FETUS WASTAGE; HUMAN; MATERNAL AGE; MATERNAL SERUM; PREGNANCY; PREGNANCY TERMINATION; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY; ULTRASOUND;

ADULT; ALPHA-FETOPROTEINS; AMNIOCENTESIS; ANEUPLOIDY; CHORIONIC GONADOTROPIN; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; KARYOTYPING; MATERNAL AGE; MIDDLE AGED; NECK; PREGNANCY; PREGNANCY, HIGH-RISK; RISK FACTORS; ULTRASONOGRAPHY, PRENATAL;

EID: 0034760360     PISSN: 10153837     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053943     Document Type: Article

References (19)

1. Antenatal screening for Down's syndrome
2. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
3. The incorporation of maternal age into the sonographic scoring index for the detection at 14-20 weeks of fetuses with Down's syndrome
4. Can the presumed risk of autosomal trisomy be decreased in fetuses of older women following a normal sonogram?
5. New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age
6. Randomised study of risk of fetal loss related to early amniocentesis versus chronic villus sampling
7. Group randomised trial to assess safety fetal outcome of early midtrimester amniocentesis
8. Fetal loss rate after second trimester amniocentesis at different gestational age
9. Randomised controlled trial of genetic amniocentesis in 4,606 low-risk women
10. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening. A prospective study
11. Chromosomal defects and outcome in 1,015 fetuses with increased nuchal translucency
12. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation
13. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old
14. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening
15. A high-sensitivity alternative to 'routine' genetic amniocentesis: Multiple urinary analytes, nuchal thickness, and age
16. A survey of attitudes about maternal serum screening for fetal chromosome abnormalities in women 35 years of age and older
17. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome
18. Effect of first trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
19. Prenatal screening for Down syndrome: Should first trimester ultrasound replace maternal serum screening?